[ Do Not Miss ] 7 Small Cap Stocks That Are Trending Right Now

See which stocks have been rated by 3 or more analysts in the last few days. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [You Don't Want To Miss This - Put December 28th On Your Calendar]( [Get the Full Story Here]( --------------------------------------------------------------- December 23, 2022 From the desk of the Editor (Trending Small Cap Report) Dear Reader, We just identified 7 Small Cap stocks that have above average price targets according to the firms listed below. Today’s report includes Analyst coverage from the following firms; Evercore ISI, H.C. Wainwright, Barclays, SVB Securities, and Oppenheimer. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message [“Infinite Energy”: New AI Tech Unleashes Largest Untapped Energy Source on Earth]( A tiny Silicon Valley company is using artificial intelligence to unleash the largest untapped energy source in the world. I’m not talking about oil, gas, wind, solar, hydro, nuclear … or anything you’ve likely heard about before… Yet this breakthrough is set to help launch an era of cheap, abundant electricity the likes of which the world has never seen. In fact, the growth here could be almost unimaginable. [To get the whole story, including details of the company responsible, click here now…]( --------------------------------------------------------------- [Rocket Pharmaceuticals, RCKT]( Recent Analyst Action: Joshua Schimmer, analyst at Evercore ISI, reiterates coverage on [Rocket Pharmaceuticals (RCKT)](in the Healthcare sector with a Buy rating and a price target of $75.00 (1 day ago). - Recent Price: $18.31 - Average Analyst Price Target: $50.88 (177.88%) - Market Cap: $1.51B [TipRanks.com]( also reports that [Rocket Pharmaceuticals](currently has 12 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $50.88. The target pricing ranges from a high forecast of $75.00 down to a low forecast of $17.78. [Rocket Pharmaceuticals (RCKT)](’s last closing price was $18.31 which would put the average price target at $50.88. Here are 3rd party ratings for [RCKT](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 26% (65 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [New Documentary: The Two Men Destroying America]( This is causing a lot of controversy… It’s a new documentary called [The Two Men Destroying America.]( And a lot of powerful people would rather this exposé never saw the light of day. Chances are, they’ll attempt to have it scrubbed from existence. That’s because it tells the true (and terrifying) story of how two men from New York have engineered a reset of not just your personal wealth, but the entire US economic system. [Click play to watch The Two Men Destroying America]( --------------------------------------------------------------- [Altimmune, ALT]( Recent Analyst Action: Patrick Trucchio, analyst at H.C. Wainwright, reiterates coverage on [Altimmune (ALT)](in the Healthcare sector with a Buy rating and a price target of $50.00 (2 days ago). - Recent Price: $15.04 - Average Analyst Price Target: $30.33 (101.66%) - Market Cap: $769.83M [TipRanks.com]( also reports that [Altimmune](currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $30.33. The target pricing ranges from a high forecast of $50.00 down to a low forecast of $20.00. [Altimmune (ALT)](’s last closing price was $15.04 which would put the average price target at $30.33. Here are 3rd party ratings for [ALT](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 36% (89 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [Arcus Biosciences, RCUS]( Recent Analyst Action: Peter Lawson, analyst at Barclays, reiterates coverage on [Arcus Biosciences (RCUS)](in the Healthcare sector with a Buy rating and a price target of $35.00 (2 days ago). - Recent Price: $21 - Average Analyst Price Target: $43.86 (108.86%) - Market Cap: $1.55B [TipRanks.com]( also reports that [Arcus Biosciences](currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $43.86. The target pricing ranges from a high forecast of $60.00 down to a low forecast of $33.00. [Arcus Biosciences (RCUS)](’s last closing price was $21 which would put the average price target at $43.86. Here are 3rd party ratings for [RCUS](: - TipRanks.com: Strong Buy - TradingView.com: Sell - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 26% (65 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [These 2 Dividend Stocks Pay Every Week]( you still looking for consistent income in this near-zero interest rate environment? There is a better way. I just revealed the Holy Grail of dividend stocks - a safe, reliable and consistent stock that [pays dividends EVERY single week](- 52 times a year. It's simple: Buy the stock this Monday and you'll get your first dividend payout in your bank account this Thursday....and then every Thursday after for as long as you own the stock! [Tap here to reveal the name of this stock for FREE.]( --------------------------------------------------------------- [NewAmsterdam Pharma Company, NAMS]( Recent Analyst Action: Roanna Ruiz, analyst at SVB Securities, reiterates coverage on [NewAmsterdam Pharma Company (NAMS)](in the Healthcare sector with a Buy rating and a price target of $19.00 (3 days ago). - Recent Price: $11.495 - Average Analyst Price Target: $21.50 (87.04%) - Market Cap: $956.36M [TipRanks.com]( also reports that [NewAmsterdam Pharma Company](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $21.50. The target pricing ranges from a high forecast of $24.00 down to a low forecast of $19.00. [NewAmsterdam Pharma Company (NAMS)](’s last closing price was $11.495 which would put the average price target at $21.50. Here are 3rd party ratings for [NAMS](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Top 36% (89 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [Viking Therapeutics, VKTX]( Recent Analyst Action: Jay Olson, analyst at Oppenheimer, reiterates coverage on [Viking Therapeutics (VKTX)](in the Healthcare sector with a Buy rating and a price target of $13.00 (3 days ago). - Recent Price: $8.09 - Average Analyst Price Target: $14.40 (78.00%) - Market Cap: $620.41M [TipRanks.com]( also reports that [Viking Therapeutics](currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $14.40. The target pricing ranges from a high forecast of $21.00 down to a low forecast of $11.00. [Viking Therapeutics (VKTX)](’s last closing price was $8.09 which would put the average price target at $14.40. Here are 3rd party ratings for [VKTX](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 26% (65 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [The Best $1 Investment You Can Make Today]( 1 doesn’t go very far these days... but now you can get stock recommendations from 5 investing titans [for just $1!]( --------------------------------------------------------------- [Verona Pharma, VRNA]( Recent Analyst Action: Ram Selvaraju, analyst at H.C. Wainwright, reiterates coverage on [Verona Pharma (VRNA)](in the Healthcare sector with a Buy rating and a price target of $32.00 (2 days ago). - Recent Price: $24.1 - Average Analyst Price Target: $29.80 (23.65%) - Market Cap: $1.62B [TipRanks.com]( also reports that [Verona Pharma](currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.80. The target pricing ranges from a high forecast of $33.00 down to a low forecast of $26.00. [Verona Pharma (VRNA)](’s last closing price was $24.1 which would put the average price target at $29.80. Here are 3rd party ratings for [VRNA](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 26% (65 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- [Zymeworks, ZYME]( Recent Analyst Action: Gena Wang, analyst at Barclays, reiterates coverage on [Zymeworks (ZYME)](in the Healthcare sector with a Hold rating and a price target of $9.00 (1 day ago). - Recent Price: $8.47 - Average Analyst Price Target: $10.29 (21.49%) - Market Cap: $553.74M [TipRanks.com]( also reports that [Zymeworks](currently has 7 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.29. The target pricing ranges from a high forecast of $18.00 down to a low forecast of $7.00. [Zymeworks (ZYME)](’s last closing price was $8.47 which would put the average price target at $10.29. Here are 3rd party ratings for [ZYME](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 26% (65 out of 248) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Get Your Money Out of U.S. Banks Immediately]( A historic financial reset in 2023 could soon result in a run on the banks. Get out of cash and into a new vehicle 50 years in the making. [MORE HERE]( --------------------------------------------------------------- And there you have it--7 Small Cap Stocks that are getting attention from some of Wall Street Top Analysts. Sincerely, The Editor, MarketTickerPress.com Market Ticker Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. By opening and/or clicking a link containted within this email, you are reconfirming your opt-in status. You can unsubscribe at any time. MarketTickerPress.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | North Carolina | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software